Targeting CD47 offers several benefits in cancer therapy. By enabling the immune system to recognize and destroy tumor cells, anti-CD47 therapies can potentially enhance the efficacy of existing treatments, such as chemotherapy and immunotherapy. Additionally, this approach may help overcome resistance to traditional therapies, providing a new avenue for treating refractory cancers.
